Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to any study related procedures~* Proven prostate cancer in need for endocrine treatment, except for neoadjuvant hormonal therapy, but including patients with a rising PSA further to prostatectomy or radiotherapy~* ECOG score to be equal to or above 2~* Testosterone level within age-specific normal range~* PSA value equal to or above 2 ng/ml~* Life expectancy of at least 6 months~Exclusion Criteria:~* Previous or current hormonal treatment of prostate cancer~* Recent or current treatment with any drugs modifying the testosterone level~* Candidate for curative treatment such as prostatectomy or radiotherapy~* History of severe asthma, anaphylactic reactions, angioedema, angioneurotic oedema or Quincke's Oedema~* Hypersensitivity towards any component of degarelix or mannitol~* Cancer disease within the last 5 years except for prostate cancer and some skin cancers~* Signs of liver impairment shown as elevated serum ALT or serum bilirubin~* Known hepatic disease~* Other laboratory abnormalities that judged by the investigator would interfere with the patients participation in the trial or the evaluation of the trial results~* Clinically significant disorder including excessive alcohol or drug abuse that may interfere with trial participation or influence the conclusion of the trial as judged by the investigator~* Mental incapacity or language barrier precluding adequate understanding or cooperation~* Having received an investigational product within the last 12 weeks preceding the trial~* Previous participation in this trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 200/80 (Type: EXPERIMENTAL): Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
- Degarelix 200/120 (Type: EXPERIMENTAL): Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
- Degarelix 200/160 (Type: EXPERIMENTAL): Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
- Degarelix 240/80 (Type: EXPERIMENTAL): Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
- Degarelix 240/120 (Type: EXPERIMENTAL): Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
- Degarelix 240/160 (Type: EXPERIMENTAL): Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete